Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Anebulo Pharmaceuticals, Inc. (ANEB)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Mar-31-23 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 |
| | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | | | | | -100.0% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | | | | | | |
| Selling, general and administrative [+] | 1.8 | 1.2 | 1.0 | 0.9 | 0.9 | 0.7 | 0.3 | 0.2 |
| General and administrative | 1.8 | 1.2 | 1.0 | 0.9 | 0.9 | 0.7 | 0.3 | 0.2 |
| Research and development | 1.1 | 1.1 | 0.9 | 0.2 | 0.7 | 1.8 | 0.3 | 0.2 |
| Other operating expenses | | | | | 0.0 | | | |
| EBIT [+] | -2.9 | -2.3 | -1.9 | -1.1 | -1.6 | -2.5 | -0.6 | -0.3 |
| EBIT growth | 52.4% | -6.4% | 240.4% | 230.0% | 505.9% | 1333.3% | | |
| EBIT margin | | | | | | | | |
| Interest expense, net [+] | | 0.0 | | | | 0.0 | | |
| Interest expense | | | | | | 0.0 | | |
| Interest income | | 0.0 | | | | 0.0 | | |
| Other income (expense), net [+] | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | -26.6 | 0.0 | 0.0 |
| Other | 0.1 | | 0.0 | | | 0.0 | | |
| Pre-tax income | -2.8 | -2.3 | -1.9 | -1.1 | -1.6 | -29.1 | -0.6 | -0.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| Net income | -2.8 | -2.3 | -1.9 | -1.1 | -1.6 | -29.1 | -8.8 | -0.3 |
| Net margin | | | | | | | | |
| |
| Basic EPS [+] | ($0.11) | ($0.10) | ($0.08) | ($0.05) | ($0.07) | ($2.14) | ($0.68) | ($0.03) |
| Growth | 35.8% | -95.3% | -88.1% | 81.6% | 211.5% | 14595.0% | | |
| Diluted EPS [+] | ($0.11) | ($0.10) | ($0.08) | ($0.05) | ($0.07) | ($2.14) | ($0.68) | ($0.03) |
| Growth | 35.8% | -95.3% | -88.1% | 81.6% | 211.5% | 14595.0% | | |
| |
| Shares outstanding (basic) [+] | 25.6 | 23.3 | 23.3 | 23.3 | 23.3 | 13.6 | 13.0 | 13.0 |
| Growth | 9.8% | 71.5% | 79.8% | 79.8% | 94.5% | 13.4% | | |
| Shares outstanding (diluted) [+] | 25.6 | 23.3 | 23.3 | 23.3 | 23.3 | 13.6 | 13.0 | 13.0 |
| Growth | 9.8% | 71.5% | 79.8% | 79.8% | 94.5% | 13.4% | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|